Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

The White House has withdrawn Heidi Overton's nomination to lead the FDA, citing a lack of congressional support — just hours before a Senate committee vote. Her nomination drew fire from both Democrats and some Republicans, leaving the agency without a permanent leader once again. The FDA has been operating under acting Commissioner Kyle Diamantas since May.
The White House pulled the plug on Heidi Overton's nomination to lead the FDA late Tuesday, hours before the Senate HELP Committee was set to vote on her confirmation. A senior administration official confirmed the move, citing insufficient congressional support. Overton, a physician and deputy director of the White House Domestic Policy Council, had been nominated by President Trump in August to fill a leadership void at the agency.
Her nomination faced a rough road from the start. Democrats objected to her reluctance to publicly contradict Trump on medical misinformation, while some Republicans — including HELP Committee Chair Sen. Bill Cassidy — raised "strong concerns" about her role in efforts to alter childhood vaccine recommendations. The MAHA movement also criticized her for allegedly undermining RFK Jr.'s health agenda, and antiabortion groups questioned her stance on mifepristone access.
Key Takeaways:
Why it matters: A leaderless FDA creates regulatory uncertainty for drug and biologics sponsors at a critical time. With HHS Secretary RFK Jr. pushing a sweeping health agenda, the White House will need to move quickly to find a nominee who can win bipartisan support and stabilize one of the country's most consequential health agencies.